The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
